Evaluating RXI-109 to Reduce the Progression of Subretinal Fibrosis in Subjects With NVAMD

NCT02599064 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

9

Enrollment

INDUSTRY

Sponsor class

Conditions

Age-related Macular Degeneration
Subfoveal Choroidal Neovascularization
Subretinal Scarring
Subretinal Fibrosis

Interventions

DRUG: RXI-109

Sponsor

RXi Pharmaceuticals, Corp.